New hope for hard-to-treat cancers: triple-drug combo targets HER2-positive tumors
NCT ID NCT07506057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (trastuzumab, serplulimab, and chemotherapy) in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and improve survival. Participants must have HER2-overexpressing tumors and be between 18 and 75 years old.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?